Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline
Next Steps May Depend On Longer-Term Open-Label Data
Executive Summary
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
You may also be interested in...
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Prevention Better Than Cure? AC Immune's Parkinson’s Vaccine Approach
With a broad pipeline focused on neurodegenerative disease, AC Immune is about to begin a Phase II program investigating an alpha-synuclein-targeted peptide vaccine with a diagnostic to stratify patients.
AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.